- Home
- OZ vs DRUG Comparison
OZ vs DRUG Comparison
Compare OZ & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- DRUG
- Stock Information
- Founded
- OZ 2020
- DRUG 2019
- Country
- OZ United States
- DRUG United States
- Employees
- OZ N/A
- DRUG N/A
- Industry
- OZ
- DRUG Pharmaceuticals and Biotechnology
- Sector
- OZ
- DRUG Health Care
- Exchange
- OZ Nasdaq
- DRUG Nasdaq
- Market Cap
- OZ 237.6M
- DRUG 199.7M
- IPO Year
- OZ N/A
- DRUG N/A
- Fundamental
- Price
- OZ $63.88
- DRUG $34.74
- Analyst Decision
- OZ
- DRUG Strong Buy
- Analyst Count
- OZ 0
- DRUG 7
- Target Price
- OZ N/A
- DRUG $83.25
- AVG Volume (30 Days)
- OZ 2.1K
- DRUG 37.4K
- Earning Date
- OZ 01-01-0001
- DRUG 08-13-2025
- Dividend Yield
- OZ N/A
- DRUG N/A
- EPS Growth
- OZ N/A
- DRUG N/A
- EPS
- OZ N/A
- DRUG N/A
- Revenue
- OZ $4,077,000.00
- DRUG N/A
- Revenue This Year
- OZ N/A
- DRUG N/A
- Revenue Next Year
- OZ N/A
- DRUG N/A
- P/E Ratio
- OZ N/A
- DRUG N/A
- Revenue Growth
- OZ 94.70
- DRUG N/A
- 52 Week Low
- OZ $56.77
- DRUG $0.94
- 52 Week High
- OZ $82.89
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- OZ 39.75
- DRUG 64.45
- Support Level
- OZ $65.25
- DRUG $31.80
- Resistance Level
- OZ $65.87
- DRUG $36.50
- Average True Range (ATR)
- OZ 0.45
- DRUG 2.47
- MACD
- OZ -0.22
- DRUG 0.65
- Stochastic Oscillator
- OZ 0.00
- DRUG 71.01
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.